Neutralization of the Cytotoxic Effect of Anti-αGal Antibodies with Monoclonal Anti-idiotypic Antibodies
The use of the pig (or other widely divergent species) as a donor of organs for humans is dependent upon the development of a successful method of overcoming the hyperacute rejection (as well as any subsequent immune response) that is mounted in humans against grafted pig organs. The initiating factor in this hyperacute rejection is believed to be the presence of preformed antibodies in the recipient’s serum [1–4]. Recipient xenoreactive antibodies bind target molecules on the vascular endothelial cell surface of the xenografted organ and activate complement, leading to endothelial cell destruction and resulting in interstitial hemorrhage and edema.
KeywordsCarbohydrate Europe Lymphoma Myeloma Galactose
Unable to display preview. Download preview PDF.
- 3.Paul, L.C. Mechanism of humoral xenograft rejection. In: Cooper, D.K.C., et al., (eds) Xenotransplantation. Springer, Heidelberg, 1991, p. 47Google Scholar
- 4.Piatt, J.L. Bach, F.H. Mechanism of tissue injury in hyperacute xenograft rejection. In: Cooper, D.K.C., et al., (eds) Xenotransplantation. Springer, Heidelberg, 1991, p. 69Google Scholar
- 7.Cooke, A. Regulation of the immune response. In: Roitt, L, et al. (eds) Immunology. Mosby-Year Book, Europe, Ltd., London, 1993, p. 94Google Scholar
- 8.Koren E, Milotic F, Neethling FA, Koscec M, Fei D, Kobayashi T, Taniguchi S, Cooper DKC. Murine monoclonal anti-idiotypic antibodies directed against human anti-αGal antibodies reduce in vitro and in vivo cytotoxicity of human and baboon sera to pig cells in culture: implications for pig-to-human organ xenotransplantation. Transplantation, 1996; 62:837PubMedCrossRefGoogle Scholar
- 9.Goding, J.W. Production of monoclonal antibodies. In: Goding, J.W. Monoclonal Antibodies: Principles and Practice. Academic Press, London, 1986, p.71Google Scholar
- Kobayashi, T., Taniguchi, S. Ye, Y et al. Prolongation of graft survival following pig-to-baboon heart transplantation by cobra venom factor (CVF) without natural antibody depletion. Submitted for publicationGoogle Scholar
- 23.Woodie, E.S., Thistlewaite, J.R., Jolliffe, L.K., et al. Humanized antibodies: successful transfer of immune modulating properties and idiotype expression. J. Immunol., 1992; 148:2756Google Scholar
- 25.Amlot, P.L., Stone, MJ., Cunningham, D., et al. A phase I study of an anti-CD22-degly-cosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 1993; 82:2624Google Scholar
- 26.Grossbard, M.L., Gribben, J.G., Freedman, A.S., et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin’s lymphoma. Blood, 1993; 81:2263Google Scholar